Corrigendum to “Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy” [Biomaterials 312 (2025) 122750

Mostafa Yazdimamaghani; Oleg V. Kolupaev; Chaemin Lim; Duhyeong Hwang; Sonia J. Laurie; Charles M. Perou; Alexander V. Kabanov; Jonathan S. Serody

doi:10.1016/j.biomaterials.2024.122831

journal article·2025-03Open access

Corrigendum to “Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy” [Biomaterials 312 (2025) 122750

Mostafa Yazdimamaghani, Oleg V. Kolupaev, Chaemin Lim, Duhyeong Hwang, Sonia J. Laurie, Charles M. Perou, Alexander V. Kabanov, Jonathan S. Serody

Biomaterials· Volume 314

Publisher page Open full text

Source abstract

Abstract

Corrigendum to "Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy"

The source flagged this abstract for review. Check formulas and completeness against the original publication.

Source: openaire · Quality: needs review · Source record ↗
Source flags: short_text

Research context

Nanomaterials Biomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Stress, Anesthesia, and Immune Response · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References

Reference metadata was not supplied for this record.